Hjem › Nyrekreft › New York › New York City
Kliniske studier for Nyrekreft i New York City, NY
15 studier for Nyrekreft søker deltakere på steder i og rundt New York City (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
RekruttererFase 1
- Research Site, New York
- Research Site, New York
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RekruttererFase 1
- NEO-811 NYC Site, New York
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
RekruttererFase 1
- Memorial Sloan Kettering Cancer Center, New York
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
RekruttererFase 3
- Research Site, New York
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekruttererObservasjonsstudie
- NYU Langone Medical Center, New York
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RekruttererFase 1/2
- Icahn School of Medicine at Mount Sinai, New York
- Evelyn H. Lauder Breast and Imaging Center (BAIC), New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
- og 1 flere
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RekruttererFase 1
- Memorial Sloan Kettering Cancer Center, New York
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
RekruttererFase 1
- Xencor Investigative Site, New York
- Xencor Investigative Site, New York
A Study of a Side Effects and Resource Navigation Program for People With Cancer
Rekrutterer
- City College of New York (Data Collection AND Specimen Analysis), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Brodalumab in the Treatment of Immune-Related Adverse Events
RekruttererFase 1
- Columbia University Irving Medical Center, New York
Kidney Cancer DNA Registry
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Memorial Sloan Kettering Cancer Center, New York
Decision Aid (DA) for Renal Patients
Rekrutterer
- NYU Langone Health, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RekruttererFase 1/2
- NYU Langone Health, New York
Nyrekreft-studier i andre byer
- Boston, MA12 studier
- Nashville, TN12 studier
- Houston, TX10 studier
- San Diego, CA9 studier
- St. Louis, MO9 studier
- Dallas, TX9 studier
- Washington, DC9 studier
- Seattle, WA8 studier
- Edison, NJ8 studier
- Miami, FL8 studier
- Los Angeles, CA7 studier
- Rochester, MN7 studier
Andre studier i New York City
- Brystkreft136 studier
- Ikke-småcellet lungekreft121 studier
- Kreft (alle typer)109 studier
- Prostatakreft103 studier
- Metastatisk kreft93 studier
- Kolorektal kreft78 studier
- Eggstokkreft69 studier
- Lungekreft60 studier
- Multipelt myelom60 studier
- Pankreaskreft60 studier
- Endometriekreft52 studier
- Akut myelogen leukemi51 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.